GLOBALMED TECHNOLOGIES USA, INC.
FL, FLORIDA

GlobalMed Technologies USA Inc., commonly known as GMT, is a biomedical technology company incorporated in Florida on March 14, 2016. The company specializes in the manufacturing, distribution, and implementation of an advanced Photonic Corpuscular Irradiation System. This system includes key components such as the GMT PCI 1 Blood Irradiator, GMT Disposable Kit, and the GMT Cuvette (Irradiation Chamber). Initially focused on treating severe and catastrophic diseases like HIV/AIDS, Ebola, Leishmaniasis, and Hepatitis C, GMT is poised to expand its services to include solutions for Laminitis in animals and sterilization processes crucial to the Blood Bank Industry. Notably, GMT is pioneering an Organ Transplant Sterilization Process designed to mitigate organ rejection, potentially eliminating the need for anti-rejection medications. The company holds patents on its processes, products, and technologies. In 2003, it secured a U.S. patent for its innovative treatment methods. A significant milestone was reached in 2004 with a government-approved Phase I Controlled Clinical Trial involving 36 patients with acute and chronic HIV/AIDS. The trial's findings were promising: viral loads decreased by 85 to 99%, CD4-cell levels stabilized, opportunistic infections were entirely eliminated, and participants did not require antiviral medications. GlobalMed Technologies is headquartered at 11530 SW 33 Terrace, Miami, FL 33165, and maintains an operational presence in Miami-Dade County. The company's mission emphasizes providing affordable biomedical treatments to underserved populations worldwide. It is led by Danilo O Fernandez as President/Designate (P/D). The organization continues its operations under the filing number P16000024115, with Federal Employer Identification Number 32-0510184.